Leap Therapeutics, Inc. (LPTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LPTX
- Company Leap Therapeutics, Inc.
- Price $0.69
- Changes Percentage 19.02
- Change 0.1103
- Day Low $0.61
- Day High $0.69
- Year High $3.58
- Year Low $0.22
- Market Cap $23,453,100
- Price Avg 50 EMA (D) $0.71
- Price Avg 200 EMA (D) $0.45
- Exchange NASDAQ
- Volume 61,718
- Average Volume 26,085,927
- Open $0.64
- Previous Close $0.58
- EPS -1.58
- PE -0.36
- Earnings Announcement 2025-11-12 13:30:00
- Shares Outstanding $41,392,694
Company brief: LEAP THERAPEUTICS, INC. (LPTX )
- Healthcare
- Biotechnology
- Mr. Douglas E. Onsi J.D.
- https://www.leaptx.com
- US
- N/A
- 01-25-2017
- US52187K2006
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.